In short
This article discusses a clinical trial investigating the use of a new drug combination for patients with advanced ovarian cancer who have previously been treated with PARP inhibitors. The study focuses on combining tuvusertib, an ATR inhibitor, with either niraparib (a PARP inhibitor) or lartesertib (an ATM inhibitor) to assess their efficacy and safety in treating epithelial ovarian cancer that has progressed despite prior PARP inhibitor therapy.
At a glance
- Study Type
- Open-label, multicenter, randomized Phase 2 study
- Target Population
- Patients with advanced epithelial ovarian cancer that progressed on prior PARP inhibitor therapy
- Intervention
- Tuvusertib combined with either Niraparib or Lartesertib
- Primary Objectives
- 1. Assess efficacy (Objective Response); 2. Evaluate safety and tolerability
- Key Inclusion Criteria
- - Confirmed high-grade serous or endometrioid ovarian cancer; - BRCA mutations or positive HRD status; - Disease progression on PARP inhibitor therapy; - Measurable disease per RECIST v1.1
- Key Exclusion Criteria
- - Primary platinum-refractory disease; - Active brain metastases; - Active/uncontrolled infection; - History of organ transplantation
- Primary Endpoints
- 1. Confirmed Objective Response; 2. Number of participants with treatment-emergent adverse events
Overview of Tuvusertib
Tuvusertib, also known as 8-(1,3-dimethylpyrazol-4-yl)-1-(3-fluoro-5-methoxypyridin-4-yl)-7-methoxy-3-methylimidazo[4,5-c]quinolin-2-one, is a promising new medication being studied for the treatment of advanced ovarian cancer. It is specifically designed for patients whose cancer has progressed after previous treatment with a type of drug called a PARP inhibitor.
How Tuvusertib Works
Tuvusertib is classified as an ATR inhibitor. ATR stands for Ataxia Telangiectasia and Rad3-related protein, which is an important enzyme in the body that helps cancer cells repair their DNA and survive. By blocking this enzyme, tuvusertib may help prevent cancer cells from repairing themselves, potentially making them more vulnerable to other treatments.
Current Clinical Trial
A clinical trial called "DDRiver EOC 302" is currently underway to study tuvusertib in combination with other medications for patients with advanced ovarian cancer. This trial is specifically for patients who have:
- Epithelial ovarian cancer: This is the most common type of ovarian cancer, which starts in the cells that cover the outer surface of the ovary.
- Cancer that has progressed after previous treatment with a PARP inhibitor: PARP inhibitors are a type of targeted therapy used in ovarian cancer treatment.
- Certain genetic mutations: Specifically, mutations in genes called BRCA1 or BRCA2, or tumors with a characteristic called "homologous recombination deficiency" (HRD).
Eligibility Criteria
To participate in this study, patients must meet several criteria, including:
- Have confirmed high-grade serous or high-grade endometrioid ovarian, primary peritoneal, or fallopian tube cancer that has come back after previous treatment.
- Have tumors with specific genetic characteristics (BRCA mutations or HRD positive status).
- Have experienced disease progression while on PARP inhibitor therapy, but have benefited from it for at least 6 months before the progression.
- Have measurable disease according to specific criteria (RECIST v1.1).
- Be in relatively good overall health, with an ECOG performance status of 0 or 1 (meaning they are able to carry out light to moderate physical activities).
There are also several factors that would exclude a patient from participating, such as having certain other medical conditions or a history of other cancers.
Study Design
The study is designed to test tuvusertib in combination with two other drugs:
- Tuvusertib + Niraparib: Niraparib is a PARP inhibitor, which is already used in ovarian cancer treatment.
- Tuvusertib + Lartesertib: Lartesertib is an ATM inhibitor, another type of drug that affects how cancer cells repair their DNA.
Patients in the study will be randomly assigned to receive one of these combinations. The main goals of the study are to assess how effective these combinations are in treating the cancer and to evaluate their safety.
Potential Benefits and Risks
While tuvusertib shows promise, it's important to remember that it is still being studied and its full effects are not yet known. Potential benefits could include shrinking tumors or slowing the progression of cancer. However, as with any medical treatment, there may also be risks and side effects.
The study will carefully monitor patients for any adverse effects. Some common side effects of cancer treatments can include fatigue, nausea, and changes in blood cell counts, but the specific side effects of tuvusertib are still being determined through this research.